Treatment of Primary HIV-1 Infection with Cyclosporin A Coupled with Highly Active Antiretroviral Therapy

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2002 Mar 6

PMID 11877476

Citations 43

Authors

G Paolo Rizzardi

Alexandre Harari

Brunella Capiluppi

Giuseppe Tambussi

Kim Ellefsen

Donatella Ciuffreda

Patrick Champagne

Pierre-Alexandre Bart

Jean-Philippe Chave

Adriano Lazzarin

Giuseppe Pantaleo

Affiliations

Soon will be listed here.

Abstract

Primary HIV-1 infection causes extensive immune activation, during which CD4(+) T cell activation supports massive HIV-1 production. We tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection. Nine adults with primary HIV-1 infection were treated with CsA along with HAART. At week 8, all patients discontinued CsA but maintained HAART. Viral replication was suppressed to a comparable extent in the CsA + HAART cohort and in 29 control patients whose primary infection was treated with HAART alone. CsA restored normal CD4(+) T cell levels, both in terms of percentage and absolute numbers. The increase in CD4(+) T cells was apparent within a week and persisted throughout the study period. CsA was not detrimental to virus-specific CD8(+) or CD4(+) T cell responses. At week 48, the proportion of IFN-gamma-secreting CD4(+) and CD4(+)CCR7(-) T cells was significantly higher in the CsA + HAART cohort than in the HAART-alone cohort. In conclusion, rapid shutdown of T cell activation in the early phases of primary HIV-1 infection can have long-term beneficial effects and establish a more favorable immunologic set-point. Appropriate, immune-based therapeutic interventions may represent a valuable complement to HAART for treating HIV infection.

Citing Articles

Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial.

Llanos Jimenez L, Alvarez-Alvarez B, Fonseca Aizpuru E, Peces-Barba G, Pindao Quesada G, Rodriguez Nieto M J Clin Med. 2024; 13(17).

PMID: 39274454 PMC: 11396137. DOI: 10.3390/jcm13175242.

The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection.

Mazzuti L, Turriziani O, Mezzaroma I Biomedicines. 2023; 11(1).

PMID: 36672667 PMC: 9856151. DOI: 10.3390/biomedicines11010159.

CCR5-Δ32 gene variant frequency in the Nigerian and Zimbabwean populations living in North Cyprus.

Ndikom B, Ergoren M, Sayan M, Mocan G, Fahrioglu U Afr Health Sci. 2022; 22(1):361-366.

PMID: 36032469 PMC: 9382466. DOI: 10.4314/ahs.v22i1.44.

Lv T, Cao W, Li T J Immunol Res. 2021; 2021:7316456.

PMID: 34631899 PMC: 8494587. DOI: 10.1155/2021/7316456.

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?.

Devaux C, Melenotte C, Piercecchi-Marti M, Delteil C, Raoult D Front Med (Lausanne). 2021; 8:663708.

PMID: 34552938 PMC: 8450353. DOI: 10.3389/fmed.2021.663708.

References

Chun T, Engel D, Berrey M, Shea T, Corey L, Fauci A . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95(15):8869-73. PMC: 21169. DOI: 10.1073/pnas.95.15.8869. View

Bass H, Nishanian P, Hardy W, Mitsuyasu R, Esmail E, Cumberland W . Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin Immunol Immunopathol. 1992; 64(1):63-70. DOI: 10.1016/0090-1229(92)90060-2. View

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

Fleury S, de Boer R, Rizzardi G, Wolthers K, Otto S, Welbon C . Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med. 1998; 4(7):794-801. DOI: 10.1038/nm0798-794. View

McCune J, Hanley M, Cesar D, Halvorsen R, Hoh R, Schmidt D . Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest. 2000; 105(5):R1-8. PMC: 377453. DOI: 10.1172/JCI8647. View

Pantaleo G, Cohen O, Schacker T, Vaccarezza M, Graziosi C, Rizzardi G . Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med. 1998; 4(3):341-5. DOI: 10.1038/nm0398-341. View

Sallusto F, Mackay C, Lanzavecchia A . The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000; 18:593-620. DOI: 10.1146/annurev.immunol.18.1.593. View

Berrey M, Schacker T, Collier A, Shea T, BRODIE S, Mayers D . Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis. 2001; 183(10):1466-75. DOI: 10.1086/320189. View

Andrieu J, Even P, Venet A, Tourani J, Stern M, Lowenstein W . Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol. 1988; 47(2):181-98. DOI: 10.1016/0090-1229(88)90071-2. View

10.

Musey L, Krieger J, Hughes J, Schacker T, Corey L, McElrath M . Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis. 1999; 180(2):278-84. DOI: 10.1086/314868. View

11.

Phillips A, Wainberg M, Coates R, Klein M, Rachlis A, Read S . Cyclosporine-induced deterioration in patients with AIDS. CMAJ. 1989; 140(12):1456-60. PMC: 1269983. View

12.

Emmel E, Verweij C, Durand D, Higgins K, Lacy E, Crabtree G . Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science. 1989; 246(4937):1617-20. DOI: 10.1126/science.2595372. View

13.

Pantaleo G, Fauci A . New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol. 1995; 13:487-512. DOI: 10.1146/annurev.iy.13.040195.002415. View

14.

Fleury S, Rizzardi G, Chapuis A, Tambussi G, Knabenhans C, Simeoni E . Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2000; 97(10):5393-8. PMC: 25839. DOI: 10.1073/pnas.97.10.5393. View

15.

Soudeyns H, Pantaleo G . The moving target: mechanisms of HIV persistence during primary infection. Immunol Today. 1999; 20(10):446-50. DOI: 10.1016/s0167-5699(99)01504-2. View

16.

Oxenius A, Price D, Easterbrook P, OCallaghan C, Kelleher A, Whelan J . Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000; 97(7):3382-7. PMC: 16248. DOI: 10.1073/pnas.97.7.3382. View

17.

Ascher M, Sheppard H . AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol. 1988; 73(2):165-7. PMC: 1541594. View

18.

Rosenberg E, Altfeld M, Poon S, Phillips M, Wilkes B, Eldridge R . Immune control of HIV-1 after early treatment of acute infection. Nature. 2000; 407(6803):523-6. DOI: 10.1038/35035103. View

19.

Pantaleo G . How immune-based interventions can change HIV therapy. Nat Med. 1997; 3(5):483-6. DOI: 10.1038/nm0597-483. View

20.

Schacker T, Collier A, Hughes J, Shea T, Corey L . Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996; 125(4):257-64. DOI: 10.7326/0003-4819-125-4-199608150-00001. View